MRNA Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
No risks detected for MRNA from our risk checks.
Moderna, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$79.83|
|52 Week High||US$217.25|
|52 Week Low||US$62.55|
|1 Month Change||4.76%|
|3 Month Change||-29.08%|
|1 Year Change||-56.22%|
|3 Year Change||-47.66%|
|5 Year Change||329.19%|
|Change since IPO||329.19%|
Recent News & Updates
Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024Nov 03
Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value EstimateOct 18
Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?May 23
Weak Statutory Earnings May Not Tell The Whole Story For Moderna (NASDAQ:MRNA)Mar 03
Earnings Working Against Moderna, Inc.'s (NASDAQ:MRNA) Share Price Following 28% DiveFeb 25
Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 48% Discount?Feb 08
Moderna revises COVAX deal to offer updated COVID-19 vaccinesOct 17
Moderna: A Look At The Monster ROICOct 08
Moderna gets EMA review for Omicron BA.4/BA.5 targeting booster shot for aged 12, aboveSep 28
EMA aims to start review of Moderna's Omicron BA.4/5 adapted shot by end of SeptemberSep 20
Moderna CEO open to providing COVID shots to China; mulls building mRNA facility in Japan - ReutersSep 14
Pfizer/BioNTech's Omicron-targeting booster vaccine gets approval in UKSep 05
|MRNA||US Biotechs||US Market|
Return vs Industry: MRNA underperformed the US Biotechs industry which returned -7.7% over the past year.
Return vs Market: MRNA underperformed the US Market which returned 11.9% over the past year.
|MRNA Average Weekly Movement||7.0%|
|Biotechs Industry Average Movement||11.4%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: MRNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MRNA's weekly volatility (7%) has been stable over the past year.
About the Company
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
|MRNA fundamental statistics|
Is MRNA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MRNA income statement (TTM)|
|Cost of Revenue||US$10.33b|
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-9.09|
|Net Profit Margin||-38.00%|
How did MRNA perform over the long term?See historical performance and comparison